Streetbeat News

Analyst Ratings

AVGO

Susquehanna analyst Christopher Rolland maintains a Positive rating on Broadcom (NASDAQ:AVGO) and raises the price target from $1400 to $1550.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 3:49 pm

XNCR

RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Xencor (NASDAQ:XNCR) and maintained a $32 price target.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 3:49 pm

ATSG

Susquehanna analyst Christopher Stathoulopoulos has maintained a Neutral rating on Air Transport Services Group (ATSG) and lowered the price target from $15 to $14.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 3:48 pm

VERV

RBC Capital analyst Luca Issi has reiterated an Outperform rating on Verve Therapeutics (NASDAQ:VERV) and maintained a $35 price target.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 3:47 pm

AMBA

Susquehanna analyst Christopher Rolland has maintained a Positive rating on Ambarella (NASDAQ:AMBA) and increased the price target from $70 to $80.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 3:47 pm

UPST

Investors have shown mixed sentiment in Upstart Holdings (NASDAQ:UPST) through options trading, with an equal split between bullish and bearish positions. Benzinga's options scanner revealed 10 significant transactions, indicating a price target range of $25.0 to $35.0 for UPST. The stock is currently trading at $25.75, down by -1.79%, with an RSI suggesting a neutral position. Analyst ratings from JP Morgan and Piper Sandler set an average price target of $26.0, with ratings of Underweight and Neutral, respectively.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 3:46 pm

DVN

Devon Energy (NYSE:DVN) has seen a significant uptick in options activity, with a bullish sentiment from deep-pocketed investors according to Benzinga's tracking. The activity includes 8 notable options trades, with 62% bullish and 37% bearish sentiment, aiming for a price range of $37.5 to $50.0. The company, a major player in North American oil and gas exploration, has a current stock price of $44.25, with indicators suggesting it may be approaching overbought territory.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 3:46 pm

DAWN

Piper Sandler analyst Joseph Catanzaro maintains an Overweight rating on Day One Biopharmaceutical (NASDAQ:DAWN) but lowers the price target from $45 to $40.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 3:45 pm

FULC

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Fulcrum Therapeutics (NASDAQ:FULC) and increased the price target from $13 to $15.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 3:44 pm

CAVA

Piper Sandler analyst Brian Mullan has maintained an Overweight rating on Cava Group (NYSE:CAVA) and increased the price target from $46 to $63.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 3:42 pm